Patient Enrollment Completed for Opvika Phase I/II Clinical Trial in the U.S

WUHAN, China and SAN DIEGO, Feb. 19, 2024. Neurophth Therapeutics, Inc. ( " Neurophth " ) announced today that the last patient has been enrolled in Phase I/II clinical trial of Opvika (Esonadogene Imvoparvovec) for the treatment of Leber hereditary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials